Terrascend
TED.F- 1M
- -11.8%
Terrascend in brief
Terrascend is a listed company in the Pharmaceutical industry, based in Canada. It was founded in 2017. Its market value was $146 M on 31 October 2026, which makes it the 17,338th largest listed company in the world and the 617th largest in Canada on this site. In the year to December 2025 it had sales of $261 M and a net loss of $81 M. By market, the largest shares of its 2025 sales came from Canada (under 1%). Its shares trade under the symbol TED.F (Frankfurt).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Terrascend
TERRASCEND is a vertically integrated cannabis company providing industry product selection to both the medical and legal adult-use markets. It operations in Pennsylvania, New Jersey, Michigan and California, licensed cultivation and processing operations in Maryland and licensed production in Canada. The headquarters is in Canada.
Terrascend company annual revenue was 247 million USD and annual net loss was -303 million USD for year ending December 2022.
Terrascend timeline
- 2017
- 🏁· approximateFounded
Events of Terrascend from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #489 (Jan 2020) · #257 (Jan 2021) · #264 (Jan 2022) · #367 (Dec 2022) · #365 (Jul 2023) · #321 (Jan 2024) · #613 (Sep 2026) · #617 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.5×
- Price / book
- 1.5×
- Free cash flow yield
- 8.8%
- Net margin (TTM)
- -6.7%
- Operating margin
- 16.1%
- Return on equity
- -18.1%
- Liabilities / assets
- 82.2%
- Net debt
- $188M
- Revenue growth
- -2.8%
- R&D / revenue
- 0.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $261M | -2.8% | $42M | $-81M | -31.2% |
| Dec 2024 | $268M | +7.0% | $39M | $-73M | -27.1% |
| Dec 2023 | $251M | +1.1% | $30M | $-87M | -34.6% |
| Dec 2022 | $248M | +27.6% | $-336M | $-325M | -131.3% |
| Dec 2021 | $194M | +47.0% | $23M | $6M | 3.2% |
| Dec 2020 | $132M | — | $21M | $-142M | -107.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $22M | $9M | $13M | $-0.29 | — |
| Dec 2024 | $38M | $7M | $31M | $-0.28 | — |
| Dec 2023 | $27M | $5M | $23M | $-0.34 | — |
| Dec 2022 | $-26M | $40M | $-66M | $-1.35 | — |
| Dec 2021 | $-32M | $40M | $-72M | $0.01 | — |
| Dec 2020 | $-37M | $44M | $-81M | $-1.03 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $68M (+4.8% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 20268-KCurrent reportResults of operations
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Aug 25, 20268-KCurrent reportShareholder vote · Regulation FD disclosure · Other events
- Aug 6, 20268-KCurrent reportResults of operations · Directors or officers changed · Regulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jul 6, 2026DEF 14AProxy statement
- Jun 29, 20268-KCurrent reportOther events
- Jun 25, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure
- Jun 15, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 7, 20268-KCurrent reportResults of operations
- May 7, 202610-QQuarterly report · period to Mar 2026
- Apr 27, 20268-KCurrent reportResults of operations
Official filings of Terrascend with the US Securities and Exchange Commission.
Annual results
- Revenue
- $261 M
- Operating income
- $42 M
- Net income
- $-81 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $557 M
- Total liabilities
- $458 M
- Total equity
- $99 M
As of December-2025
Insider trading at Terrascend#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lynn K. GefenChief People and Legal Officer | Shares withheld for tax | -7,412 | $0.660 | $5 K | 1.08 M | Form 4 |
| filed | Ziad GhanemPresident and CEO | Shares withheld for tax | -22,017 | $0.660 | $15 K | 2.86 M | Form 4 |
| filed | Lynn K. GefenChief People and Legal Officer | Shares withheld for tax | -5,591 | $0.620 | $3 K | 1.09 M | Form 4 |
| filed | Ziad GhanemPresident and CEO | Shares withheld for tax | -9,998 | $0.620 | $6 K | 2.89 M | Form 4 |
| filed | Lynn K. GefenChief People and Legal Officer | Shares withheld for tax | -50,879 | $0.680 | $35 K | 1.09 M | Form 4 |
| filed | Ziad GhanemPresident and CEO | Shares withheld for tax | -105,051 | $0.680 | $71 K | 2.90 M | Form 4 |
| filed | Lynn K. GefenChief People and Legal Officer | Grant or award | +540,254 | — | — | 1.15 M | Form 4 |
| filed | Ziad GhanemPresident and CEO | Grant or award | +1.39 M | — | — | 3.00 M | Form 4 |
Markets and events: Terrascend#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0.6M |
| Q2 2026 | Q2 2026 | $0.3M |
| Q1 2026 | Q1 2026 | $0.1M |
| Q4 2025 | Q4 2025 | $0M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0.1M |
| Q1 2025 | Q1 2025 | $0.2M |
| Q4 2024 | Q4 2024 | $0.1M |
Terrascend scorecard#
Passes 10 of the 26 checks that could be worked out: strongest in valuation (3 of 6), weakest in growth (2 of 6). Fiscal year 2025; market cap of Oct 31, 2026.
Valuation3 of 6
Growth2 of 6
Profitability2 of 5
Financial health2 of 6
Shareholder returns1 of 3
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Terrascend's statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 16.1% | 1.8% | |
| Net margin | -31.2% | -1.5% | |
| Return on equity | -59.0% | -0.9% | |
| Revenue growth, 3 years a year | 1.7% | 2.5% | |
| Revenue growth | -2.8% | 7.3% | |
| Debt to equity | 2.28× | 0.66× |
4of 9on the Piotroski tests of financial strength
- Revenue fell 2.8% against the year before.
- Net loss of $81 million, the 4th loss-making year in a row.
- Operating income covers the interest bill only 1.5 times.
- Goodwill and intangibles ($277 million) exceed shareholders' equity ($99 million).
Terrascend: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 261 | 268r | 251r | 248 | 194 | 132 | |
| Cost of revenue | 124 | 132r | 112r | 146 | 82 | 46 | |
| Gross profit | 136 | 136r | 138r | 102 | 113 | 86 | |
| Research and development | — | — | — | — | — | 0.1 | |
| Selling, general and administrative | — | — | 115 | 116 | 75 | 61 | |
| Selling and marketing | — | — | 9.7 | 10 | 1.9 | 1.7 | |
| General and administrative | 86 | 91r | 84r | 116 | 75 | 61 | |
| Operating expenses | 94 | 97r | 108r | 437 | 90 | 65 | |
| Operating income | 42 | 39r | 30r | −336 | 23 | 21 | |
| Interest expense and finance costs | 29 | 27r | 31r | 27 | 21 | 2.0 | |
| Other non-operating income (expense) | 0.9 | 0.9r | −0.8r | 0.2 | 0.2 | −0.4 | |
| Income before tax | 5.0 | 4.2r | −4.2r | −310 | 45 | −117 | |
| Income tax | 29 | 25r | 23r | −11 | 29 | 11 | |
| Income from continuing operations | −29 | −28r | −36r | −304 | 13 | −139 | |
| Income from discontinued operations | −57 | −52 | −59r | −26 | −9.5 | −15 | |
| Minority interests' share of net income | 4.9 | 7.6 | 8.8 | 4.6 | 3.0 | — | |
| Net income attributable to shareholders | −81 | −73 | −87 | −325 | 6.1 | −142 | |
| Earnings per share, basic | -0.29 | -0.28 | -0.34r | -1.35 | 0.02 | -1.03 | |
| Earnings per share, diluted | -0.29 | -0.28 | -0.34r | -1.35 | 0.01 | -1.03 | |
| Shares, weighted average (basic) | 301 | 292 | 279 | 244 | 181 | 150 | |
| Shares, weighted average (diluted) | 301 | 292 | 279 | 244 | 209 | 150 | |
| Balance sheet | |||||||
| Cash and cash equivalents | 37 | 26 | 22 | 26 | 80 | — | |
| Short-term investments | 0.4 | 1.7 | 1.9 | 3.6 | — | — | |
| Receivables | 17 | 20r | 19 | 22 | 12r | — | |
| Inventory | 34 | 40r | 52 | 46 | 36r | — | |
| Other current assets | 8.6 | 5.1r | 4.9 | 5.5r | 5.0r | — | |
| Current assets | 110 | 177r | 103 | 122 | 172r | — | |
| Property, plant and equipment | 130 | 124r | 196 | 216 | 112r | — | |
| Right-of-use (leased) assets | 27 | 29r | 43 | 29 | 43r | — | |
| Goodwill | 110 | 107 | 107r | 90 | 90 | 73 | |
| Other intangible assets | 167 | 170 | 216 | 240 | 168r | — | |
| Non-current assets | 447 | 430r | 564 | 580 | 409r | — | |
| Total assets | 557 | 607r | 667 | 702 | 582r | — | |
| Accounts payable | 40 | 40r | 50 | 44 | 28r | — | |
| Debt due within a year | — | — | 126 | 39 | — | — | |
| Current liabilities | 80 | 91r | 207 | 138 | 66r | — | |
| Lease liabilities (non-current) | 29 | 31r | 45 | 32 | 31 | — | |
| Non-current liabilities | 378 | 339r | 219 | 243 | 287r | — | |
| Total liabilities | 458 | 430r | 426 | 380 | 353r | — | |
| Retained earnings | −865 | −779 | −704 | −618 | −315 | — | |
| Minority interests | 1.5 | −0.1 | −1.8 | 2.4 | 5.4 | 3.8 | |
| Total equity | 99 | 177 | 241 | 321 | 229 | −13 | |
| Total liabilities and equity | 557 | 607r | 667 | 702 | 582r | — | |
| Shares outstanding | 309 | 293 | 288 | 260 | 191 | — | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 5.4 | 5.1r | 5.8r | 9.7 | 5.5 | 3.9 | |
| Share-based compensation | 5.0 | 9.7 | 7.7 | 12 | 15 | 10 | |
| Cash from operating activities | 22 | 38 | 27 | −26 | −32 | −37 | |
| Capital expenditure | −8.6 | −6.9r | −4.9r | −40 | −40 | −44 | |
| Intangible assets bought | −0.7 | −1.2 | −1.7r | −2.3 | −0.4 | −0.8 | |
| Cash from investing activities | −15 | −12 | −16 | −28 | −132 | −46 | |
| Debt issued | 79 | 129 | 24 | 43 | 0.8 | 196 | |
| Debt repaid | −70 | −137r | −43r | −42 | −4.5 | −49 | |
| Shares bought back | −0.4 | −0.2 | — | — | — | — | |
| Cash from financing activities | 4.2 | −25 | −13 | 3.7 | 182 | 133 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
What Terrascend sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- 🇨🇦 Canada$1 M0.3%-18%
As of Dec 31, 2025
Where Terrascend operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 61 subsidiaries on file.
Events at Terrascend#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 6 · Material agreement 3 · Agreement ended 3 · New debt 3 · Unregistered share sale 4 · Shareholder vote 4 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Restructuring | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officersUnregistered share sale | 8-K | |
| Unregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
As of Nov 5, 2026
Acquisitions and funding#
10 acquisitions, $516 M paid where reported · 7 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Ratio Cannabis LLC | 2025 | — | $10 M | — | Annual report |
| Peninsula | 2023 | — | $15 M | 100% | Annual report |
| Herbiculture | 2023 | — | $8 M | 100% | Annual report |
| Blue Ridge | 2023 | — | $6 M | 100% | Annual report |
| Gage Growth Corp | 2022 | — | $330 M | — | Annual report |
| Pinnacle | 2022 | — | $31 M | — | Annual report |
| KISA Enterprises MI, LLC and KISA Holdings, LLC | 2022 | — | $31 M | — | Annual report |
| AMMD | 2022 | — | $10 M | 100% | Annual report |
| New Jersey Partnership | 2021 | — | $50 M | 93.75% | Annual report |
| HMS | 2021 | — | $24 M | 100% | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2026 | $22 M | Private placement after listing | $10 to $50 million | 8 | debt, options | SEC |
| May 2020 | $21 M | No. 7 | $10 to $50 million | 25 | equity, options | SEC |
| Jan 2020 | $4 M | No. 6 | $2 to $10 million | 2 | debt, options | SEC |
| Jan 2020 | $4 M | No. 5 | $2 to $10 million | 10 | debt, options | SEC |
| Dec 2019 | $23 M | No. 4 | $10 to $50 million | 24 | debt, options | SEC |
| Nov 2019 | $2 M | No. 3 | $2 to $10 million | 2 | debt, options | SEC |
| Jun 2019 | $38 M | Issued in a merger or acquisition | $10 to $50 million | 8 | equity | SEC |
| May 2019 | $20 M | No. 2 | $10 to $50 million | 13 | equity | SEC |
| May 2019 | $23 M | No. 1 | $10 to $50 million | 50 | equity | SEC |
How Terrascend compares in Pharmaceutical
- Market cap$146 M · higher than 21% of 393
- Revenue$261 M · higher than 33% of 324
- Net margin-6.7% · higher than 21% of 313
- Revenue growth-2.8% · higher than 19% of 107
- Price / sales0.6× · lower than 93% of 219
- Price / book1.5× · lower than 67% of 207
- FCF yield8.8% · higher than 81% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Terrascend🇨🇦 | $146 M | — | -6.7% | -2.8% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Windlas Biotech Limited$214 M
- Venus Remedies Limited$215 M
How current the figures are
- Market cap:
- Oct 31, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 21, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Terrascend? Verify and update this profile — free
Show Terrascend's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.